Valiant Laboratories Ltd. successfully conducts 5th AGM, approves financial statements and director re-appointments

Valiant Laboratories Limited held its 5th Annual General Meeting (AGM) on Monday, September 28, 2026, at 11:30 AM IST, conducted through Video Conference/Other Audio Visual Means. The meeting addressed several key resolutions, including the adoption of the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026.

Further, the shareholders approved the re-appointment of Mr. Sandeep Gupta as a Non-Executive Director retiring by rotation, and the re-appointment of Mr. Santosh Vora as Managing Director for a period of 5 years. The meeting also saw the approval of the second term for Mrs. Sonal Vira as an Independent Director for five consecutive years, along with revised remuneration for Mr. Paresh Shah (Whole-Time Director and Chief Financial Officer) and commission payments to Non-Executive Directors Mr. Shantilal Vora, Mr. Sandeep Gupta, and Independent Directors Mr. Mulesh Savla and Mrs. Sonal Vira.

Additionally, resolutions were passed for the approval of material related party transactions involving Valiant Organics Limited, Valiant Advanced Sciences Private Limited, Aarti Pharmalabs Limited, and Alchemie Speciality Chemicals Private Limited. The continuation of Mr. Shantilal Vora's Directorship upon attaining 75 years and the shifting of the Registered Office outside the jurisdiction of the existing Registrar of Companies within Maharashtra were also approved. The Scrutinizer's Report dated September 29, 2026, and the Voting Results pursuant to Regulation 44 of the Listing Regulations were submitted.